Claims
- 1. A compound of the following formula:
- 2. A compound according to claim 1, wherein
R3 are the same or different and independently selected from the group consisting of:
H; C1-C4-straight chain alkyl; and C3-C4-branched chain alkyl; Y=
H; OR1; N(R1)2; N(R1)C(O)R3; N(R1)SO2R3; or N(R1)C(O)NHR3.
- 3. A compound of the following formula:
- 4. A method of treating a mammal with cancer selected from the group consisting of breast cancer, colon cancer, central nervous system cancer, leukemia, melanoma, lung cancer, ovarian cancer, prostate cancer, and renal cancer, comprising:
administering a therapeutically effective amount of the compound of claim 1 to the mammal under conditions effective to treat the cancer.
- 5. The method of claim 4, wherein the mammal is human.
- 6. A pharmaceutical composition of matter comprising the compound of claim 1 and one or more pharmaceutical excipients.
- 7. A method of treating a mammal with cancer selected from the group consisting of breast cancer, colon cancer, central nervous system cancer, leukemia, melanoma, lung cancer, ovarian cancer, prostate cancer, and renal cancer, comprising:
administering a therapeutically effective amount of the compound of claim 3 to the mammal under conditions effective to treat the cancer.
- 8. The method of claim 7, wherein the mammal is human.
- 9. A pharmaceutical composition of matter comprising the compound of claim 3 and one or more pharmaceutical excipients.
- 10. A process for preparation of a purine derivative compound of the formula:
- 11. A process according to claim 10, wherein if Y is NHR1, said process further comprises:
reacting the purine derivative compound with R3C(O)Cl or R5C(O)Cl or R3SO2Cl or R3NCO or R6OC(O)Cl under conditions effective to form a final product having the same formula as the purine derivative compound except that Y is NR1C(O)R3 or NR1C(O)R5 or NR1SO2R3 or NR1C(O)NHR3 or NR1C(O)OR6.
- 12. A process according to claim 10 further comprising:
reacting a second intermediate compound of the formula: 126with a second compound of the formula: 127wherein: V1=
NH2; OH; SH; under conditions effective to form the first intermediate compound.
- 13. A process according to claim 12 further comprising:
reacting a third intermediate compound of the formula: 128with a compound of the formula: R1—Z under conditions effective to form the second intermediate compound.
- 14. A process according to claim 10, wherein the purine derivative compound has the formula:
- 15. A process for preparation of a purine derivative compound of the formula:
- 16. A process according to claim 15 further comprising:
reacting a second intermediate compound of the formula: 132with a second compound of the formula: 133under conditions effective to form the first intermediate compound.
- 17. A process according to claim 16 further comprising:
reacting a third intermediate compound of the formula: 134with a compound of the formula: (R2—B(OH)2) or (R2—Sn(n-Bu)3 or R2—SnMe3), or mixtures thereof, under conditions effective to form the second intermediate compound.
- 18. A process according to claim 15 further comprising:
reacting a fourth intermediate compound of the formula: 135with a compound of the formula: (R2—B(OH)2) or (R2—Sn(n-Bu)3 or R2—SnMe3), or mixtures thereof, under conditions effective to form the first intermediate compound.
- 19. A process according to claim 18 further comprising:
reacting a fifth intermediate compound of the formula: 136with a compound of the formula: 137under conditions effective to form the fourth intermediate compound.
- 20. A process according to claim 15, wherein the purine derivative compound has the formula:
- 21. A process for preparation of a purine derivative compound of the formula:
- 22. A process according to claim 21, wherein if Y is NHR1, said process further comprises:
reacting the purine derivative compound with R3C(O)Cl or R5C(O)Cl or R3SO2Cl or R3NCO or R6OC(O)Cl under conditions effective to form a final product having the same formula as the purine derivative compound except that Y is NR1C(O)R3 or NR1C(O)R5 or NR1SO2R3 or NR1C(O)NHR3 or NR1C(O)OR6.
- 23. A process according to claim 21 further comprising:
reacting a second intermediate compound of the formula: 142with a compound of the formula R1—Z where Z=Br or I, under conditions effective to form the first intermediate compound.
- 24. A process according to claim 23 further comprising:
reacting a third intermediate compound of the formula: 143with a compound of the formula 2,6-dichloropurine (Formula IV) under conditions effective to form the second intermediate compound.
- 25. A process according to claim 24 further comprising:
reacting a fourth intermediate compound of the formula: 144with a compound of the formula: (R2—B(OH)2) or (R2—Sn(n-Bu)3 or R2—SnMe3), or mixtures thereof, under conditions effective to form the third intermediate compound.
- 26. A process according to claim 21, wherein the purine derivative compound has the formula:
- 27. A process for preparation of a purine derivative compound of the formula:
- 28. A process according to claim 27 further comprising:
reacting a second intermediate compound having the same formula as the first intermediate compound except that Y is NH2, with R8CH2Z or R8CHO under conditions effective to form the first intermediate compound where Y=NHR1 or N(R1)2, wherein Z is Br or I, wherein R8 is C1-C5-straight chain alkyl, C2-C5-straight chain alkenyl, C3-C5-branched alkyl chain, C3-C5-branched alkenyl chain, (C3-C7-cycloalkyl), CF3, or CH2CF3.
- 29. A process for preparation of a purine derivative compound of the formula:
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Patent Application Serial No. 60/318,569, filed on Sep. 11, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60318569 |
Sep 2001 |
US |